Maureen Canavan, PhD, MPH
Associate Research Scientist (General Medicine)Cards
About
Titles
Associate Research Scientist (General Medicine)
Affiliated Faculty, Yale Institute for Global Health
Biography
Maureen E. Canavan, Ph.D., is an epidemiologist at Yale Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) since 2017. In addition to working the MCBS data, she works as part of the Yale Cancer Center’s Cancer Care Innovations Lab (CaCIL) team evaluating quality metrics for cancer care. Her research interests include health management, employment, and end of life care. Prior to her work at COPPER, she was a member of the Global Health Leadership Institute (GHLI) team, she conducts qualitative and quantitative data analysis of GHLI studies in countries including Ghana, Ethiopia and China. She received an M.P.H. from the University of Medicine and Dentistry of New Jersey, School of Public Health and a B.S. from Pennsylvania State University.
Appointments
General Internal Medicine
Associate Research ScientistPrimary
Other Departments & Organizations
- COPPER Center
- General Internal Medicine
- Internal Medicine
- Obesity Research Working Group
- Yale Institute for Global Health
Education & Training
- PhD
- Yale University Graduate School (2011)
- MPH
- University of Medicine and Dentistry of New Jersey, School of Public Health, Epidemiology, Health Education, and Behavioral Science (2005)
- BS
- Pennsylvania State University, Biology (2003)
Research
Publications
2026
Updated Review: Using the National Cancer Database for Outcomes-Based Research.
Ayoade O, Caturegli G, Palis B, McCabe R, Weigel R, Canavan M, Boughey J, Boffa D. Updated Review: Using the National Cancer Database for Outcomes-Based Research. Journal Of The American College Of Surgeons 2026, 243: 696-707. PMID: 41848188, DOI: 10.1097/xcs.0000000000001924.Peer-Reviewed Original ResearchReal-World Outcomes of Induction Chemoimmunotherapy in Patients with Non-Small Cell Lung Cancer Who Have Never Smoked
Baskin A, Canavan M, Resio B, Boffa D, Caturegli G. Real-World Outcomes of Induction Chemoimmunotherapy in Patients with Non-Small Cell Lung Cancer Who Have Never Smoked. JTCVS Open 2026, 101983. DOI: 10.1016/j.xjon.2026.101983.Peer-Reviewed Original ResearchIs Pneumonectomy Appropriate after Chemoimmunotherapy? Outcomes of Neoadjuvant Chemoimmunotherapy followed by Pneumonectomy in the United States
Caturegli G, Jernigan E, Canavan M, Lynch A, Kramer R, Patil J, Esnaola G, Boffa D, Resio B. Is Pneumonectomy Appropriate after Chemoimmunotherapy? Outcomes of Neoadjuvant Chemoimmunotherapy followed by Pneumonectomy in the United States. JTCVS Open 2026, 102048. DOI: 10.1016/j.xjon.2026.102048.Peer-Reviewed Original ResearchIs Pneumonectomy Appropriate after Chemoimmunotherapy? Outcomes of Neoadjuvant Chemoimmunotherapy followed by Pneumonectomy in the United States
Caturegli G, Jernigan E, Canavan M, Lynch A, Kramer R, Patil J, Esnaola G, Boffa D, Resio B. Is Pneumonectomy Appropriate after Chemoimmunotherapy? Outcomes of Neoadjuvant Chemoimmunotherapy followed by Pneumonectomy in the United States. JTCVS Open 2026, 102047. DOI: 10.1016/j.xjon.2026.102047.Peer-Reviewed Original ResearchTreatment and Prognosis of Thymic Neuroendocrine Neoplasms in the United States
Caturegli G, Patil J, Lynch A, Canavan M, Jernigan E, Esnaola G, Boffa D, Resio B. Treatment and Prognosis of Thymic Neuroendocrine Neoplasms in the United States. Annals Of Thoracic Surgery Short Reports 2026 DOI: 10.1016/j.atssr.2026.06.035.Peer-Reviewed Original ResearchHigh‐Risk Medication Prescribing Among Older Adults in the Emergency Department: A National Assessment
Follman S, Canavan M, Rothenberg C, Iscoe M, Venkatesh A, Ramachandran R, Gettel C. High‐Risk Medication Prescribing Among Older Adults in the Emergency Department: A National Assessment. Academic Emergency Medicine 2026, 33: e70321. PMID: 42136546, DOI: 10.1111/acem.70321.Peer-Reviewed Original ResearchCounty-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care
Gaddy J, Lee D, Herrin J, Yu J, Pollack C, Dean L, Dougherty G, Canavan M, Soulos P, Gross C. County-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care. JAMA Network Open 2026, 9: e2613919. PMID: 42160049, PMCID: PMC13191378, DOI: 10.1001/jamanetworkopen.2026.13919.Peer-Reviewed Original ResearchThis study examined whether structural barriers at the county level influence differences in care and outcomes across racial groups among patients with non–small cell lung cancer (NSCLC), the most common type of lung cancer.Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer
Caturegli G, Canavan M, Ayoade O, Boffa D, Resio B. Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer. Clinical Lung Cancer 2026, 27: 48-54.e2. PMID: 42070908, DOI: 10.1016/j.cllc.2026.03.016.Peer-Reviewed Original ResearchReal-world period prevalence of psoriatic disease 2015-2025: A cross-sectional study in the Epic Cosmos database
Lee M, Canavan M, Cohen J. Real-world period prevalence of psoriatic disease 2015-2025: A cross-sectional study in the Epic Cosmos database. Journal Of The American Academy Of Dermatology 2026, 95: 181-183. PMID: 41903709, DOI: 10.1016/j.jaad.2026.03.067.Peer-Reviewed Original ResearchUse of Complementary and Alternative Medicine in the Management of Breast Cancer
Ayoade O, Caturegli G, Canavan M, Resio B, Berger E, Boffa D. Use of Complementary and Alternative Medicine in the Management of Breast Cancer. JAMA Network Open 2026, 9: e260337. PMID: 41770560, PMCID: PMC12954545, DOI: 10.1001/jamanetworkopen.2026.0337.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- January 08, 2026Source: JCO Podcast
Podcast: Association Between EOL SACT and Healthcare Utilization
- October 22, 2025Source: Cure
Improving End-of-Life Care: Making Hospice and Home Support Accessible
- May 28, 2025
United by Cancer Research: One Mission. One Voice
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO